mix neulasta enbrel resili sensipar face new at-risk
gener launch esa continu weak enbrel price stabil
growth side aimovig/repatha growth impact weak price trend new
guidanc rais bottom end rang overal trim ep
new pt base price-to-earnings sotp analysi
neulasta post stronger expect despit strong biosimilar entri udenyca
estim expect soft trend overal believ neulasta eros
line better expect sensipar face at-risk launch put
pressur trend henc trim estim litig on-going
parallel would rather leav settlement upsid given risk launch
recal teva launch at-risk settl admit limit visibl
settlement prospect gener new project assum
complet gener convers might overli pessimist
look ahead suggest abil stabil ep despit pressur
base outlook ahead cogniz year full pressur
neulasta sensipar face genet start worst case scenario
despit outlook suffici resili top-lin along tight opex
control stock buyback keep ep rel flat even may provid near
term boost given low investor expect
thesi stock pipelin key futur sentiment shift stock
turnaround stori highlight deep earli stage oncolog pipelin
data continu showcas breadth also hematolog would
also welcom busi develop activ help build later stage pipelin
appreci deal may incur dilut appli pressur
expenditur could bring forth growth faster would help expand price-to-earnings
base irrevers coval bind mutat kra protein
dose qd drug highli select enabl reach target dose rapidli
patient current enrol expans cohort analysi
discuss kol anticip respons rate lower
lung cancer even combotherapi may need yield high respons rate
durabl note even lower respons rate highli encourag
kol view respons rate monotherapi lung cancer
encourag could short monotherapi respons
rate month would accept durabl lung cancer prior
target therapi ras-raf-mek pathway guid
pleas see page report import disclosur
like fundament due diversifi product mix biolog franchis
durabl protect product innov pipelin tight control opex
aggress cash return sharehold see near-term risk enbrel sensipar
gener challeng new product launch includ aimovig biosimilar
provid new growth prospect legaci franchis declin opinion amgen
continu provid sustain growth navig turbul water
legaci franchis erod meantim tezepelumab earli stage oncolog pipelin
gain visibl shore confid long term prospect
district court decis enbrel patent
infring suit sandoz
data phase studi kra inhibitor
updat sensipar gener litig
data bite platform --
grow dividend consist stock
neulasta enbrel sensipar eros
less expect
aimovig biosimilar tezepelumab
tezepelumab success becom
revenu growth greater
pipelin contribut substanti
valu model
biosimilar launch exceed
neulasta rapid share loss sensipar
tezepelumab drug
aimovig slow
fail rais dividend pursu
success navig biosimilar competit legaci franchis
still contend patent challeng age brand nevertheless tight opex
control margin expans stock buyback new product launch ep growth
resili manag grow dividend annual major brand includ enbrel
sale neulasta denosumab franchis brand xgeva cancer
prolia osteoporosi sale aranesp/epogen like
tezepelumab asthma earli stage oncolog pipelin solid liquid tumor
biosimilar franchis aimovig also provid attract growth venu
move test next also explor combo
target therapi part futur develop sens combotherapi
make sens monotherapi better shot lung cancer ultim
like explor combo tumor view
cowen compani
amgen annual model y/i erythropoietin enbrel growth sale g-csf growth dmab growth kyproli growth probabl product sale growth revenu growth good sold margin loss affili margin product incom growth share outstand ep exclud fasb abp stock compens expens merger-rel item ep cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
forecast sale product difficult outlook could alter
competit clinic develop failur reimburs chang new competit
could also impact sale estim pipelin product might fail develop
risk includ clinic develop regulatori price commerci challeng may
prevent financi forecast materi
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
